Company Information


ResMed Inc (ASX: RMD)

RMD:NYQ, also known as Resmed Inc., produces medical devices and software for the healthcare market. ResMed has recently completed two acquisition deals. On September 29, 2023, they finalized the purchase of KC Machine LLC, acquiring a 44.51% stake in the company at a transaction value of $2.60 million. The second deal completed was with Somnoware Healthcare Systems Inc on July 5, 2023, although the percentage acquired and the transaction value were not disclosed.

As of the last recorded data on December 31, 2023, First Sentier Investors (Hong Kong) Ltd. held 9.55 million shares in Resmed Inc., representing a 0.65% stake. Following closely, Vanguard Investments Australia Ltd. owned 8.72 million shares, accounting for 0.59% as of March 31, 2024. Schroder Investment Management (Singapore) Ltd. held 5.61 million shares (0.38%) as of January 31, 2024. Australian Foundation Investment Co. Ltd. (Investment Management) reported a 0.30% stake with 4.39 million shares as of June 30, 2023. Lastly, First Sentier Investors (Australia) IM Ltd. held 4.26 million shares, a 0.29% stake as of December 31, 2023. Additional shareholding is noted from FIL Investment Management (Singapore) Ltd. with 3.38 million shares representing 0.23%.

Financial details such as the income statement for Resmed Inc. are currently unavailable. The company offers tools such as a Growth Calculator Beta to explore financial concepts like the time value of money and the benefits of saving over time. For those interested in monitoring financial markets and events, features like Alerts for immediate notifications and the option to create Watchlists for a curated list of assets are available.


Top Australian Brokers



ResMed Inc (ASX: RMD) Live Chart


ResMed Inc (ASX: RMD) Forecast

Analysts from Wall Street have provided their 12-month price targets for ResMed. On average, they have set the target at $216.75. The highest target set by an analyst is $238.00 while the lowest is $195.00. Compared to ResMed’s last trading price of $217.89, the average target suggests a slight decrease of 0.52%.


ResMed Inc (ASX: RMD) Performance


ResMed Inc (ASX: RMD) Fundamentals


ResMed Inc (ASX: RMD) Competitors


Don’t Buy Just Yet

You will want to see this before you make any decisions.

Before you decide which shares to add to your portfolio you might want to take a look at this special report we recently published.

Our experts picked out The 5 best ASX shares to buy in 2024.

We’re giving away this valuable research for FREE.

Click below to secure your copy